Identifying biomarkers in tissue and fluid samples from colorectal cancer patients
Official title: Novel Colon Cancer Markers in Gastrointestinal Tissue and Biofluids
Run by Vanderbilt University Medical Center · NCT00899626 · Data updated 2026-11-12
This study is trying to find new markers in tissue and fluid samples from people with colorectal cancer and healthy volunteers to see if they can help identify cancer risk and improve screening methods.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Vanderbilt University Medical Center Academic / other |
| Locations | 2 sites (Nashville, Tennessee and 1 other locations) |
| Status | Recruiting |
| Started | June 2002 |
| Main results expected | October 2045 |
| Study ends | October 2045 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT00899626 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals undergoing colonoscopy or endoscopy for diagnostic or screening purposes who have a diagnosis of gastrointestinal cancer, polyps, or inflammatory bowel disease.
✕Probably not a fit
Patients who do not require colonoscopy or endoscopy and do not have a history of gastrointestinal issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify new potential biomarkers associated with gastrointestinal cancers by analyzing tissue and biological fluid samples from patients undergoing colonoscopy, endoscopy, or surgery. Participants include both cancer patients and healthy volunteers, with samples collected for proteomic analysis to discover substances that may indicate cancer risk. The study also seeks to develop new screening strategies based on these biomarkers. Participants will be followed for up to five years to assess the prognostic significance of identified biomarkers.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and early detection strategies for gastrointestinal cancers.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for cancer detection, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS: * Undergoing colonoscopy or endoscopy for diagnostic or screening purposes at the Vanderbilt University Medical Center or at the Veterans Affairs Medical Center AND * Meets 1 of the following criteria: * Diagnosis of gastrointestinal (GI) cancer, polyps, or inflammatory bowel disease * History of previously treated GI cancer, polyps, or inflammatory bowel disease PATIENT CHARACTERISTICS: * Capable of giving informed consent * Not mentally or medically impaired * No bleeding disorder PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Where it's running
-
Veterans Affairs Medical Center - Nashville
Nashville, Tennessee, United States Recruiting -
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States Recruiting
Study contacts
- Study coordinator: Kristen K Ciombor, MD
- Email: kristen.k.ciombor@vumc.org
- Phone: 6159368422
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
IDOV-Immune for advanced solid tumors
This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.
-
Evaluating zanidatamab for HER2-expressing tumors
This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.
-
Evaluating BL-M17D1 for HER2 Positive Gastrointestinal Cancer
This study is testing a new drug called BL-M17D1 to see if it is safe and effective for people with advanced HER2 positive gastrointestinal cancer and other solid tumors.
-
Using 64Cu-LNTH-1363S for imaging in patients with sarcoma or gastrointestinal cancers
This study is testing a new imaging agent called 64Cu-LNTH-1363S in patients with metastatic sarcoma or gastrointestinal cancers to see how safe it is and how well it works for imaging their tumors.
-
Evaluating progastrin levels in cancer patients
This study is testing if measuring progastrin levels in the blood can help predict how cancer will progress and respond to treatment in patients with different types of cancer.
-
Detection of tumor cells and DNA in blood, urine, and bone marrow
This study is testing new ways to find cancer cells and DNA in the blood, urine, and bone marrow of people with solid tumors and those at high risk for lung cancer to help improve early detection and personalized treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.